Algernon Pharmaceuticals applies for Phase 2b/3 study on Ifenprodil in Australia
Algernon Pharmaceuticals ( CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau checked in with Steve Darling from Proactive to provide an update on the company as they seek approval in Australia for a Phase 2b/3 study of their repurposed drug Ifenprodil for coronavirus. The company already has approval in Canada and will soon apply in the United States.
Moreau telling Proactive when they get approval it will be a Phase 2b study of 100 patients between Australia, Canada and the United States. Then with positive data, the study will move directly into a Phase 3 trial.
article can be found at the following url: